313 results about "Weight gain" patented technology

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The present invention relates to the technical field of microorganisms. Disclosed are lacticaseibacillus paracasei and a postbiotic product prepared therefrom, and a use of both. The present invention provides lacticaseibacillus paracasei (Latin name) YJS05199, which has the preservation number of GDMCC No.63668, and was preserved in Guangdong Microbial Culture Collection Center on 19 July 2023. The present invention further provides a postbiotic prepared by applying the lacticaseibacillus paracasei. The lacticaseibacillus paracasei and the postbiotic prepared therefrom have a bacteriostatic effect, can inhibit the weight gain of a mouse fed with high-fat diets, reduce the adipose tissue weight and the blood glucose concentration, and can remarkably reduce the levels of TG, TC, and LDL-C in serum of the mouse. Thus, the lacticaseibacillus paracasei and the postbiotic prepared therefrom have great application prospects in preparation of products for preventing or treating obesity and related diseases or in preparation of bacteriostatic products.

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The invention discloses an obstetrical data analysis and management system based on cloud computing processing, and relates to the technical field of obstetrical data analysis and management, a data acquisition module is used for acquiring and recording current detection data of a pregnant woman and a fetus, a calculation and analysis module is used for calculating and outputting a fetus weight estimated value TE, a pregnant woman weight gain value YT and a nutrition adjustment value TQ, and the fetus weight estimated value TE, the pregnant woman weight gain value YT and the nutrition adjustment value TQ are analyzed. The regular spot check evaluation unit is used for regularly carrying out spot check on the pregnant woman subjected to current recent antenatal care, and carrying out updating calculation on a fetus weight growth reference value delta TT and a pregnant woman weight growth reference value delta YL of each week in different pregnancy periods according to age groups; large-scale data sets are efficiently processed by means of the high-performance computing power of the cloud computing platform and a computing formula, the working efficiency of obstetrical data analysis is improved, flexible adjustment is performed according to parameters corresponding to different pregnant woman age groups and pregnant periods, the corresponding parameters have a regular updating mechanism and a formed feedback mechanism, and the accuracy of the pregnant woman data analysis is improved. And the fitness and the accuracy of analysis data are ensured.

The invention relates to gestational weight gain prediction. The disclosed concepts are directed to providing protocols, solutions, concepts, designs, methods and systems related to improved prediction of gestational weight gain (GWG). Specifically, during the early stage of pregnancy (e.g., during the first 30 days of pregnancy, or during the first three months of pregnancy), a data sequence describing the weight of a pregnant subject at least twice a day (e.g., after waking up and before falling asleep) is used to determine the historical GWG curve of the subject. Since the energy balance in pregnancy is defined as energy intake equal to energy expenditure plus dynamic energy storage, a particular GWG prediction model is used to generate historical GWG curves, rather than a universal weight gain model. From the historical GWG curve, a future GWG value of the subject may be predicted. The future GWG value may be used to assess pregnancy risk scores, and / or to generate lifestyle recommendations for the subject.

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.

The invention belongs to the technical field of microorganisms, discloses a strain of pseudomonas putida and application of the strain of pseudomonas putida as fish probiotics, and particularly discloses a strain of pseudomonas putida. The invention provides a symbiotic pseudomonas putida CD separated from fish, and the strain has relatively strong fat utilization capability, can generate a plurality of beneficial extracellular metabolites, can promote metabolism of fish lipids, carbohydrates and proteins and weight gain, and also can improve the iron content and hemoglobin content in fish tissues. The pseudomonas putida strain CD disclosed by the invention has good biological safety, and has a wide development prospect in the aspect of application as fish probiotics.

The invention is a pelvic floor muscle strengthening device capable of training the pelvic floor muscles inside the body while wearing clothes and exercising in an optimal state according to the body information of the user, and includes a seat body 11, a bearing element 20 to push the pelvic floor muscle P upward, a press-adjusting means 21, detecting means 35, an electric circuitry 42, an input means 40 and a control module 45, and is operated in the manner that if the user's body weight increases, the force or compression pressing on the pelvic floor muscle P also increases.

The present invention relates to a prebiotic feed additive for promoting intestinal health of pigs, belonging to the technical field of feed, the prebiotic feed additive of the present invention comprises prebiotic components and biological adjuvants, the prebiotic components comprise oligofructose, oligoisomaltose, inulin and resistant dextrin, the biological adjuvant is a product obtained by co-enzymatic hydrolysis of dandelion and houttuynia cordata by hemicellulase and pectinase, then fermented by Lactobacillus acidophilus and Propionibacterium freudenreichii in sequence, and finally enzymatic hydrolyzed by bromelain and trypsin step by step. The components in the additive are used in combination to have a good effect of promoting intestinal health of pigs, can balance and improve the intestinal microenvironment, improve feed nutrient utilization, enhance immunity, reduce diarrheal diseases, and promote growth and weight gain.

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The present invention relates to the technical field of the development and utilization of probiotics, specifically to a Weissella confusa DY12 with probiotic activity and its application. The Weissella confusa DY12 was isolated from sheep feces. The present invention identified the probiotic effect of Weissella confusa DY12 through animal experiments. The results showed that Weissella confusa DY12 could tolerate acid and bile salts and resist the gastrointestinal internal environment; its hydrophobicity was 39.47% and its auto-aggregation was 48.12%, demonstrating that the Weissella confusa DY12 of the present invention has good intestinal adhesion ability and has the potential of probiotics. The present invention verified that Weissella confusa DY12 can effectively regulate the immune function of the animal body, improve the antioxidant capacity of the body, as well as the content of lysozyme and the activity of alkaline phosphatase, and increase the daily weight gain, ultimately improving the growth performance of animals.

The invention provides a penicillamine sustained-release preparation. The release rate of the penicillamine sustained-release preparation is adjusted through a specific sustained-release coating. Unexpectedly, the release rate can be obviously improved by adding a small amount of lactose. More unexpectedly, in the prescription system provided by the invention, under the condition that the weight gain of the sustained-release coating is the same, the penicillamine sustained-release preparation which can be released for 12 hours or 24 hours can be respectively obtained only by adjusting the content of lactose, that is, the release rate of the penicillamine sustained-release preparation in 12 hours or 24 hours can reach 85% respectively. According to the penicillamine sustained release preparation provided by the invention, the medication compliance can be improved, and the blood concentration fluctuation can be reduced.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

Described herein are compounds of Formula I:and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

The invention relates to the technical field of medicines, in particular to application of ginkgo terpene lactone to preparation of medicines for preventing or treating obesity and obesity complications and preparation of anti-aging medicines or health-care products. In a high-fat feed induced obesity model, the ginkgo terpene lactone disclosed by the invention can effectively control the weight gain of a mouse and reduce the weight of epididymis fat of the mouse, and can be used for preparing medicines for preventing and treating diet induced obesity and the like. The ginkgo terpene lactones can improve the holding power of mice and increase the muscle proportion of the mice, which shows that the ginkgo terpene lactones have a good anti-aging effect and can be used for preparing anti-aging drugs or health-care products.

The present invention relates to the application of saliva combined with lactobacillus in the preparation of a drug for treating obesity, and belongs to the field of biomedicine technology. The present invention provides the application of saliva combined with lactobacillus XA-1416 in the preparation of a drug for preventing and / or treating obesity, or preventing and / or treating obesity-related diseases. This strain can inhibit the weight gain of mice with obesity model induced by high-fat diet, reduce the blood lipid level of mice with obesity model induced by high-fat diet, improve the liver damage index of mice with obesity model induced by high-fat diet, reduce the area of ​​white fat cells in mice with obesity model induced by high-fat diet, promote the conversion of intestinal conjugated bile acid to free bile acid in mice with obesity model induced by high-fat diet, increase the level of intestinal FXR antagonist in mice with obesity model induced by high-fat diet, improve the intestinal flora imbalance of mice with obesity model induced by high-fat diet, inhibit fat accumulation in Hep G2 model, and inhibit differentiation into adipocytes in 3T3-L1 model.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

The invention discloses a feed additive for promoting muscle and gonad development of eriocheir sinensis and application of the feed additive, and relates to the technical field of aquatic feed. The feed additive comprises cholesterol and omega-3 high unsaturated fatty acid. Each kilogram of the feed comprises the following feed additives by weight: 0.4 to 4.5 g of cholesterol and 3.5 to 4.5 g of omega-3 high unsaturated fatty acid. According to the feed additive, 4.022 g / kg omega-3 high unsaturated fatty acid (omega-3 HUFA) is supplemented into feed containing 4.114 g / kg cholesterol, so that the weight gain rate, the gonad index and the meat percentage of female crabs in the fattening period can be remarkably increased; the protein nutrition deposition capability of gonads and muscles is obviously improved; when the feed added with the feed additive is used in the fattening period of the eriocheir sinensis, the feed additive has importance on nutrient deposition and quality improvement of female crabs; the production cost of farmers can be reduced, the product value is improved, and technical support is provided for healthy development of the hairy crab industry.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

Bacillus strains useful for preventing and / or controlling Clostridium perfringens infections and necrotic enteritis in monogastric animals, such as swine and poultry, and for improving the overall health, feed conversion rates and body weight gain of such animals, as well as compositions comprising the Bacillus strains and various methods of using the Bacillus strains in animal feed and animal feed additives.

To enable comprehensive health management of diet management, exercise management, sleep management, hospital visit management, and amusement management, and to solve problems such as increase in health needs and weight gain due to lack of exercise.SOLUTION: Provided is a health management system, the system comprising: diet management means, exercise management means, sleep management means, hospital visit management means, and entertainment management means.SELECTED DRAWING: Figure 1

The invention discloses a highly efficient cholesterol-lowering Lactobacillus paracasei I MAUJBC1 and its application, and relates to the technical field of functional microorganisms. The strain disclosed in the invention can alleviate weight gain caused by a high-fat diet, improve elevated blood lipid levels; reduce the expression level of cholesterol synthesis genes in the liver; significantly increase the expression level of cholesterol metabolism genes in the liver, and play a cholesterol-lowering role; and increase the abundance of beneficial bacteria in the intestinal flora, effectively improve the intestinal flora disorder caused by a high-fat diet, and play a role in alleviating hyperlipidemia.

The invention discloses a pharmaceutical application of a 3-phenylglutaric acid derivative and a pharmaceutical composition. The 3-phenylglutaric acid derivative can be used for preparing an FASN inhibition drug. The 3-phenylglutaric acid derivative micromolecule 84-B10 can inhibit FASN in a targeted manner, is used for inhibiting the activity of the FASN, promoting the degradation of the FASN and relieving weight gain, liver fat accumulation, insulin sensitivity decline and glucose tolerance impairment caused by high calorie intake, and can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases.

Described herein are GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Use of Mycobacterium vaccae, for example strain ATCC 15483, for the treatment or prevention of weight gain, visceral adipose tissue (VAT), obesity, obesity-related metabolic diseases and stress-related disorders.